What is the recommended treatment regimen and dosing for Helicobacter pylori infection in an adult patient without drug allergies, pregnancy, or severe hepatic/renal impairment?

H. pylori Treatment with Doses

For treatment-naive adults without drug allergies, bismuth quadruple therapy for 14 days is the preferred first-line regimen, consisting of: PPI (standard dose) twice daily + bismuth subsalicylate 262 mg (2 tablets) four times daily + metronidazole 500 mg three to four times daily + tetracycline 500 mg four times daily. 1

First-Line Treatment Options

All three major consensus guidelines (Toronto, Maastricht V/Florence, and ACG) agree on two primary first-line regimens 1:

Option 1: Bismuth Quadruple Therapy (PBMT) - Preferred

• PPI (standard dose twice daily):
  • Omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, esomeprazole 20 mg, rabeprazole 20 mg, or dexilant 30 mg
• Bismuth subsalicylate 262 mg: 2 tablets four times daily
  • Alternative: colloidal bismuth subcitrate 120 mg, 1 tablet four times daily
• Metronidazole 400-500 mg: three to four times daily
  • Can substitute tinidazole at equivalent dosing
• Tetracycline 500 mg: four times daily
• Duration: 14 days (Toronto and Maastricht prefer 14 days; ACG allows 10-14 days) 1

This regimen is favored because it maintains acceptable success rates even with metronidazole-resistant strains and avoids clarithromycin, which has resistance rates exceeding 30% in many regions 2, 3.

Option 2: Concomitant Non-Bismuth Quadruple Therapy (PAMC)

• PPI (standard dose twice daily)
• Amoxicillin 1000 mg twice daily
• Metronidazole 500 mg twice daily
• Clarithromycin 500 mg twice daily
• Duration: 14 days 1

This regimen is appropriate when bismuth is unavailable, particularly in areas of high clarithromycin resistance but not dual clarithromycin/metronidazole resistance 1.

Option 3: PPI Triple Therapy (Restricted Use)

• PPI (standard dose twice daily)
• Amoxicillin 1000 mg twice daily OR Metronidazole 500 mg twice daily
• Clarithromycin 500 mg twice daily
• Duration: 14 days 1

Critical caveat: This regimen is restricted to areas with documented low clarithromycin resistance (<15%) or known high local eradication success. Given current resistance patterns, this is rarely appropriate as empiric therapy 1, 4.

Duration Consensus

All guidelines converge on 14 days as the optimal duration for first-line therapy 1, 4. The Toronto Consensus explicitly states there is sufficient evidence of higher success with 14 days versus shorter durations, and recommends 14 days for all first-line treatments to maximize the chance of success on the first attempt 1, 4.

Special Populations

Penicillin Allergy

The Toronto Consensus prefers bismuth quadruple therapy based on prospective data showing superiority over clarithromycin/metronidazole triple therapy 1. Alternative: clarithromycin-based triple therapy with metronidazole only if no prior macrolide exposure (ACG) or from an area of low clarithromycin resistance (Maastricht) 1.

Second-Line (Rescue) Therapy After First Failure

Never re-use clarithromycin or levofloxacin if previously used, as resistance develops rapidly after exposure 1. The choice depends on what was used initially:

If First-Line Was Non-Bismuth Therapy:

• Bismuth quadruple therapy (PBMT) for 14 days (same dosing as above) 1

If First-Line Was Bismuth Therapy:

• Levofloxacin triple therapy for 14 days:
  • PPI (standard dose twice daily)
  • Amoxicillin 1000 mg twice daily
  • Levofloxacin 500 mg once daily OR 250 mg twice daily 1

Alternative Rescue Options:

• High-dose dual therapy (considered by all guidelines):
  • Rabeprazole 20 mg four times daily
  • Amoxicillin 750 mg four times daily
  • Duration: 14 days 1

Third-Line and Beyond

Rifabutin triple therapy should be restricted to patients who have failed at least 2-3 prior regimens 1:

• PPI (standard dose twice daily)
• Amoxicillin 1000 mg twice daily
• Rifabutin 150 mg twice daily OR 300 mg once daily
• Duration: 10 days 1

At this stage, antibiotic susceptibility testing should be strongly considered to guide regimen selection 1, 2.

Critical Pitfalls to Avoid

1. Do not use 7-10 day regimens: Outdated protocols from the 1990s achieved 90% eradication but are no longer effective due to resistance 1, 5

2. Avoid sequential and hybrid therapies: Not recommended by Toronto or Maastricht guidelines; considered "non-ideal" by ACG 1

3. Do not assume triple therapy is adequate: Standard triple therapy is no longer recommended unless antimicrobial susceptibility testing confirms sensitivity 6

4. Metronidazole can be re-used with bismuth: Unlike clarithromycin/levofloxacin, metronidazole can be repeated if given with bismuth due to synergistic effects 1

5. Amoxicillin and tetracycline can be re-used: Resistance to these agents remains rare 1

Emerging Alternatives

The 2024 ACG guidelines mention rifabutin triple therapy and potassium-competitive acid blocker (P-CAB) dual therapy as suitable empiric alternatives for 14 days in treatment-naive patients without penicillin allergy 2. However, specific dosing protocols for P-CAB dual therapy require local formulary guidance as these agents are newly approved in the United States 3.